

MANAGEMENT OF HYPERLIPIDAEMIA

C F Sum, C E Tan, L S Chew

SINGAPORE MED J 1995; Vol 36: 538

POSTSCRIPT

Since this manuscript⁽¹⁾ was submitted, two prospective trials, one on hypercholesterolaemic subjects with no history of myocardial infarction⁽²⁾ and the other in a secondary prevention setting⁽³⁾, have both shown a reduction in clinical endpoints including mortality from coronary artery disease, in subjects treated with lipid lowering drugs when compared to placebo. Importantly, this was achieved without an excess of non-cardiovascular mortality.

C F Sum
Consultant Physician & Endocrinologist
6 Napier Road #09-16/17
Gleneagles Medical Centre
Singapore 258499

C E Tan
Senior Registrar
Department of Endocrinology
Singapore General Hospital
Outram Road
Singapore 169608

L S Chew
Senior Consultant Physician & Head
Department of Medicine
Alexandra Hospital
Alexandra Road
Singapore 159964

REFERENCES

1. Sum CF, Tan CE, Chew LS. Management of hyperlipidaemia. Singapore Med J 1995; 36: 410-6.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-7.
3. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.